#USA #Precision Medicine #Morrisville #Metabolomics #Metabolon Inc

Metabolon Scientists Guest Edit Special Issue

In a significant development within the field of metabolomics, Metabolon, Inc., renowned for its cutting-edge metabolomics solutions, has announced that two of its prominent scientists, Dr. Adam Kennedy and Dr. Greg Michelotti, have been selected to guest edit a special issue of the Multidisciplinary Digital Publishing Institute's (MDPI) Metabolites journal. The special edition, titled "Advances in Metabolomics for Precision Medicine From Biomarker Discovery to Clinical Applications," is set to illuminate the latest advancements and challenges faced in using metabolomics for diagnosing diseases and monitoring patients after treatment.

A Focus on Metabolomics and Precision Medicine

This special issue will serve as a platform to showcase an array of clinical studies and experimental research utilizing animal and cellular models. These contributions aim to highlight the groundbreaking developments in metabolomics—establishing its crucial role in precision medicine. According to Dr. Adam Kennedy, who holds the position of Director of Clinical Metabolomics at Metabolon, this scientific discipline bridges the gap between genetic data and real-world patient outcomes.

"Metabolomics provides insights into the functional manifestations of our genetic code and protein functions. By integrating data from genetic backgrounds, environmental influences, and lifestyle variations, we can deepen our understanding of patient phenotypes," shares Dr. Kennedy during the announcement.

The focus on metabolomics promises to enhance both preclinical and clinical research, driving the field toward greater understanding and effectiveness in patient care and treatment plans.

Recognition of Scientific Talent

The CEO of Metabolon, Ro Hastie, expressed pride in this achievement, emphasizing that the invitation for Dr. Kennedy and Dr. Michelotti to oversee such a prestigious scientific publication reflects the company’s deep reservoir of scientific expertise. Considering the challenge of editing a leading journal like Metabolites, this accolade showcases Metabolon's commitment to advancing life sciences through metabolomics.

Call for Contributions

Researchers interested in contributing to this special issue have until July 1, 2025, to submit their manuscripts. The editors encourage submissions that delve into the recent developments and perspectives on metabolomics practices in precision medicine. Further details can be found on MDPI's journal page for Metabolites.

About Metabolon

Metabolon, Inc. stands at the forefront of the metabolomics arena with over two decades of experience, having completed more than 10,000 projects and produced in excess of 3,500 publications. With ISO 9001:2015, CLIA, and CAP certifications, the organization offers industry-leading scientific, technical, and bioinformatics expertise.

The company’s Global Discovery Panel utilizes the world's largest proprietary metabolomics reference library, which enhances their ability to provide critical insights that influence life sciences research. Metabolon’s work on metabolomics and lipidomics aids in navigating the complexities of clinical trials and product lifecycle management across a spectrum of health-related fields.

A Brief Insight into Metabolomics

Metabolomics represents a unique branch of omics science, focusing on large-scale studies of small molecules within biological systems. This comprehensive technology enables researchers to assess not just genetic variations but also how factors like medication, diet, and lifestyle interact to impact human health.

By measuring various biochemical signals, metabolomics paves the way for identifying essential biomarkers that elucidate drug mechanisms, pharmacodynamics, and safety profiles, further shedding light on individual therapeutic responses.

For additional information on Metabolon and its services, visit www.metabolon.com and connect with them on LinkedIn and Twitter.